ROCHESTER, Minn. — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women — are caused by factors other than clogged arteries, challenging long-standing assumptions about how heart attacks occur in younger populations.

Study findings published in the Journal of the American College of Cardiology examined over 15 years of data from the Rochester Epidemiology Project, providing the most comprehensive population evaluation of heart attack causes in people aged 65 and younger.

More than half of heart attacks in women under age 65 were caused by nontraditional factors, such as spontaneous coronary artery dissection (SCAD), embolism and other conditions unrelated to artery-clogging plaque. Heart attack incidence was significantly lower in women than in men — but when women did have heart attacks, the underlying causes were often misdiagnosed.

SCAD, which typically affects younger, otherwise healthy women, was frequently missed and misclassified as a typical heart attack due to plaque buildup. The most common cause of heart attack in both sexes was atherosclerosis, or artery-clogging plaque, but this accounted for only 47% of heart attacks in women, compared to 75% in men. Five-year mortality rates were highest in people who had heart attacks triggered by stressors such as anemia or infection, even though these patients had lower heart injury levels.

"This research shines a spotlight on heart attack causes that have historically been under-recognized, particularly in women," says Claire Raphael, M.B.B.S., Ph.D., an interventional cardiologist at Mayo Clinic and first author of the study. "When the root cause of a heart attack is misunderstood, it can lead to treatments that are less effective — or even harmful."

This new understanding could save lives. A misdiagnosed SCAD, for example, may be treated with a stent unnecessarily, increasing the risk of complications. Recognizing and correctly diagnosing these nontraditional heart attacks allows for more appropriate care and better long-term outcomes.

Key findings from the study:

• Out of 1,474 heart attacks, 68% were from typical plaque buildup (traditional heart disease), but nontraditional causes made up a majority of heart attacks in women.
• SCAD was nearly 6 times more common in women than men.
• Heart attacks caused by stressors such as anemia or an infection were the second-most common cause overall, and the deadliest, with a five-year mortality rate of 33%.
• Truly unexplained heart attacks were rare, making up less than 3% of cases after expert review.

Overall, the study provides insights that could reshape how heart attacks are diagnosed and managed in younger adults.

"Our research highlights the larger need to rethink how we approach heart attacks in this patient population, and for younger adult women, in particular. Clinicians must sharpen their awareness of conditions like SCAD, embolism and stress-related triggers, and patients should advocate for answers when something doesn't feel right," says Rajiv Gulati, M.D., Ph.D., chair of the Division of Interventional Cardiology and Ischemic Heart Disease at Mayo Clinic. Dr. Gulati is senior author of the study.

"Understanding why a heart attack happened is just as important as treating it," says Dr. Raphael. "It can mean the difference between recovery and recurrence."

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Terri Malloy, Mayo Clinic Communications, newsbureau@mayo.edu

The post Mayo Clinic study reveals hidden causes of heart attacks in younger adults, especially women appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — A decade after opening, the Mayo Clinic Proton Therapy Program­ in Rochester, Minnesota, has treated 10,000 patients. Annually, the program treats 30%–40% more patients than most comparable centers in the country. And, with new technology and facility expansions, it will soon be able to treat nearly 75% more patients each year with even more precise and effective therapies.

Nadia Laack, M.D., chair of the Department of Radiation Oncology at Mayo Clinic in Rochester, and Anita Mahajan, M.D., radiation oncologist and medical director of Mayo Clinic’s particle therapy center, discuss how Mayo is using tomorrow's standard of care today.

A bold step toward precision and efficiency

Mayo Clinic took a bold step by launching its program in 2015 with pencil beam scanning — an ultranarrow beam that conforms its radiation dose to the shape of the tumor. This allowed a focus on accuracy for complex tumors, many of which were considered untreatable due to their location.

Mayo Clinic, with technology vendors, has continued to elevate this therapy by developing precise tracking technology such as its custom eye-tracking device for melanoma of the eye.

The team's high level of fine-tuning extends to its scheduling. "Most proton systems have one accelerator for four rooms, treating only one at a time," explains Dr. Mahajan. "A patient could be set up in their room, but waiting an hour."

To solve this, Dr. Mahajan helped develop a system that radiation therapists use to communicate and coordinate beam use to minimize patient wait time and discomfort and allow more patients to be treated.

Locking in on a moving target

Heartbeats and breathing create constant movement in the body, making chest and abdominal tumors a moving target and previously impossible to treat safely.

"With our colleagues in Arizona and the vendor, we developed a way to track lung tumors to ensure the beam only turns on when it's within target," says Dr. Laack.

This technology helped extend proton beam therapy's effectiveness beyond cancer.

"Cardiac ablation with proton beam is an example of how we've taken everything to the next level," says Dr. Laack. "Our physicists and the Department of Cardiovascular Medicine developed tools that now allow us to confidently and accurately deliver radiation doses to the heart."

Automating an improved patient experience

Mobility restrictions and constant adjustment can be uncomfortable and time-consuming for patients. They can slow down treatment. Regular bodily functions, including gas, bowel movements and fluid retention, also require ongoing rescanning and radiation plan adjustments for treatment accuracy.

Plan adjustments previously delayed treatment by several days. Automation has helped reduce turnaround time to just one day.

"It's remarkable to have next-day planning because of automation," adds Dr. Laack. "But we can imagine a future where patients lie down comfortably, and we scan and treat them with a custom plan tailored to their current anatomy."

Building on a future-ready foundation

Mayo Clinic is amid a leap forward in heavy particle therapy, decades in the making.

"For 20 years, we've studied data and deepened our understanding of tumor genetics so we could offer the most comprehensive treatment portfolio," says Dr. Laack.

This commitment manifested in the June 2025 opening of the Duan Family Building in Jacksonville, Florida. The building will house the first carbon ion therapy facility in the Americas and introduce powerful radiation delivery for complex and proton-beam- resistant tumors.

In August 2025, the Andersen Building in Rochester also reached a major milestone, adding 360-degree gantry technology that delivers proton beam within a millimeter of accuracy and real-time CT imaging to enable faster, more precise treatment for nearly twice as many patients.

"It's an engineering marvel that represents innovation, collaboration and hope," says Dr. Laack. "It's the promise that every patient who walks through our doors will receive the most precise, personalized and compassionate care available anywhere in the world."

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and to providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Brittany Cordeiro, Mayo Clinic Communications, newsbureau@mayo.edu

The post 10 years, 10,000 lives: Mayo experts highlight the journey and future of proton beam and particle therapy at Mayo Clinic appeared first on Mayo Clinic News Network.

World Heart Day is September 29

ROCHESTER, Minn. — You may have heard of the mind-body connection: the broad concept that  thoughts and feelings, especially those related to stress, can influence physical health. Mohamad Alkhouli, M.D., an interventional cardiologist at Mayo Clinic in Rochester, Minnesota, is researching the relationship between the brain and the heart. Each can have a powerful impact on the other, Dr. Alkhouli explains.

"The mind-heart connection is part of the broader mind-body relationship, but it’s uniquely powerful. Emotional states like anxiety, grief, or even joy can directly influence heart rhythms, blood pressure, and even the risk of heart attacks," Dr. Alkhouli says. "At the same time, the heart sends signals back to the brain through nerves, hormones, and pressure receptors — affecting our mood, attention, and stress levels. So, it’s not just the brain talking to the heart; the heart talks back."

Conditions with a brain-heart connection include spontaneous coronary artery dissection (SCAD) and stress-induced cardiopathy (SICM), also known as broken heart syndrome. Both conditions can result from stress. Dr. Alkhouli has been part of Mayo Clinic research teams exploring aspects of each.

Broken heart syndrome often is sparked by stressful situations and extreme emotions; it briefly interrupts the way the heart pumps blood. People experiencing it may have sudden chest pain and think they're having a heart attack.

The tools typically used to screen for heart attacks cannot identify when broken heart syndrome is actually the cause of a patient's chest pain. In most cases, invasive coronary angiography is required to differentiate SICM from myocardial infarction due to coronary obstruction. Mayo research found that a novel technology called magnetocardiography, which measures magnetic fields generated by the heart, can help identify broken heart syndrome. 

Another Mayo study suggests that SCAD, a type of heart attack that often results from physical or emotional stress, can be a secondary event instigated by broken heart syndrome.

In broken heart syndrome, the heart's temporary weakening doesn't happen evenly: Some parts of the heart fail to contract well, while others work harder to compensate, Dr. Alkhouli says. This uneven motion creates twisting forces on the heart muscle. 

"Because the coronary arteries, the main blood vessels that supply blood to the heart, sit on top of the heart, they can be stretched or stressed at the junctions between these overactive and underactive areas during broken heart syndrome," he explains. "In some cases, this stress may cause a tear in the artery wall, what we call SCAD."

A question still to be answered is why some people develop broken heart syndrome after emotional trauma while others do not, Dr. Alkhouli notes.

Emotional stress also can increase the risk of other heart conditions, such as:

• High blood pressure, also known as hypertension.
• Heart disease.
• Atrial tachycardia.
• Bradycardia.

"What fascinates me most is how deeply intertwined our emotional and cardiovascular systems are, and how much we still don't understand," Dr. Alkhouli says. "Could we one day 'rewire' this connection for healing, using therapy, neuromodulation (alteration of nerve activity at targeted sites in the body by electrical or chemical means), or even digital tools? At Mayo Clinic, we're exploring these questions, and we're beginning to see the heart and brain not as separate organs, but as a single, dynamic network."

That network works in both directions. Dr. Alkhouli is part of Mayo's Heart Brain Clinic, where cardiologists and neurologists work together to evaluate patients who may have neurological symptoms that can be attributed to a cardiac event.

In these patients, the heart and brain are closely linked, such as strokes caused by clots that form in the heart, known as cardioembolic strokes. The causes of a transient ischemic attack, a short period of stroke-like symptoms, may include a blood clot that moves from another part of the body, such as the heart, to an artery that supplies the brain. The heart condition atherosclerosis, the buildup of fats, cholesterol and other substances in and on the artery walls, can also lead to a transient ischemic attack.  

More research is needed to better understand how to harness the mind-heart connection for disease prevention and healing. There are steps you can take now for your mental health that will benefit your heart, and things you can do for your heart health that will benefit your brain, Dr. Alkhouli says.

"The good news is that what's good for your mind is often good for your heart, and vice versa," he explains. That includes:

• Managing stress.
• Getting quality sleep.
• Staying socially connected.
• Practicing mindfulness or prayer.

"All have measurable benefits for heart health," Dr. Alkhouli says. "Likewise, regular physical activity, a heart-healthy diet and controlling blood pressure and cholesterol can boost mood and cognitive function. It's a powerful feedback loop: Caring for one supports the other."

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Sharon Theimer, Mayo Clinic Communications, newsbureau@mayo.edu

The post The brain-heart connection: Mayo Clinic expert explains powerful tie that works both ways appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — Clinicians typically classify meningiomas — the most common type of brain tumor — into three grades, ranging from slow-growing to aggressive.

But a new multi-institutional study suggests that appearances may be deceiving. If a tumor shows activity in a gene called telomerase reverse transcriptase (TERT), it tends to recur more quickly, even if it looks low-grade under the microscope.

"High TERT expression is strongly linked to faster disease progression," says Gelareh Zadeh, M.D., Ph.D., a neurosurgeon at Mayo Clinic and senior author of the study. "This makes it a promising new biomarker for identifying patients who may be at greater risk of developing aggressive disease."

An early warning sign

Meningiomas — tumors of the meninges, the protective tissue that surrounds the brain and spinal cord — are generally considered benign. But a small subset of these tumors has a mutation in the TERT gene, which is linked to faster growth and a shorter time before the tumor returns after treatment.

TERT is the active part of telomerase, an enzyme that maintains telomeres, the protective ends of chromosomes. In most healthy adult cells, TERT is switched off. But if it becomes switched back on, it can fuel cancer development by driving unchecked cell growth.

In this study, the researchers wanted to see whether high TERT expression, even in the absence of the TERT genetic mutation, also predicted worse outcomes. They looked at more than 1,200 meningiomas from patients across Canada, Germany and the U.S., and they found that nearly one-third of them had high TERT expression despite not having the mutation.

These patients had earlier tumor regrowth compared to those without TERT expression, though their outcomes were better than patients with full-blown TERT mutations.

"TERT-positive tumors behaved like they were one grade worse than their official diagnosis," says Dr. Zadeh. "For example, a grade 1 tumor with TERT expression acted more like a grade 2."

Guiding treatment decisions

The findings suggest that testing for TERT activity could help doctors predict which patients are at higher risk for recurrence and may need closer monitoring or more intensive treatment.

"Because meningiomas are the most common primary brain tumor, this biomarker could influence how thousands of patients are diagnosed and managed worldwide," says Dr. Zadeh.

"TERT expression can help us more accurately identify patients with aggressive meningiomas," Chloe Gui, M.D., a neurosurgery resident at the University of Toronto, Mayo Clinic research collaborator and the study's lead author, explains on a podcast hosted by The Lancet Oncology. "This information allows us to offer treatment tailored to the tumor's behavior." "This information allows us to offer treatment tailored to the tumor's behavior."

The team is currently investigating ways to incorporate TERT expression into the clinical workflow. The research is part of a larger effort at Mayo Clinic called the Precure initiative, focused on developing tools that empower clinicians to predict and intercept biological processes before they evolve into disease or progress into complex, hard-to-treat conditions.

Review the study for a complete list of authors, disclosures and funding. 

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and to providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Tia Ford, Mayo Clinic Communications, newsbureau@mayo.edu

The post New genetic biomarker flags aggressive brain tumors appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — A Mayo Clinic study finds that a shortened, less intense course of radiation and chemotherapy after minimally invasive surgery for HPV-positive oropharyngeal squamous cell carcinoma (HPV+OPSCC) results in less toxicity, substantially lowering the rates of treatment-related side effects while maintaining high cure rates. The findings were published in The Lancet Oncology.

"This is a game-changer for patients," says Daniel Ma, M.D., senior author of the study and head and neck radiation oncologist at Mayo Clinic Comprehensive Cancer Center. "We've significantly reduced the burden of long-term side effects without compromising the effectiveness of the treatment. This shorter, less intensive regimen allows patients to return to their lives more quickly and with a better quality of life."

Standard treatments for HPV-related oropharyngeal cancer typically involve seven weeks of daily radiation and chemotherapy, or surgery followed by six weeks of radiation and chemotherapy. While highly effective, these treatments often lead to significant long-term side effects due to high toxicity, such as jawbone failure, dry mouth, changes in taste and challenges with swallowing. "These greatly affect the quality of life for patients, many of whom are young, in their 40s and 50s," says Dr. Ma.

In the randomized phase 3 study, Mayo Clinic researchers compared the standard treatment to a new approach involving minimally invasive transoral surgery followed by a two-week course of gentler radiation therapy called de-escalated regimen of adjuvant radiotherapy (DART). DART uses about half as much radiation and a reduced dose of chemotherapy, one-fifth of the standard dose.

The results demonstrated that the less intensive treatment approach significantly reduced both severe (grade 3 or higher) and moderate (grade 2) toxicities, indicating fewer adverse events and improved symptom burden for patients following treatment. Importantly, disease control rates were comparable to the standard treatment for intermediate-risk patients.

For specific high-risk patients, namely those with five or more lymph nodes and disease extending outside of the lymph nodes, the standard treatment showed slightly better disease control, potentially due to chemotherapy-related factors rather than radiation. The researchers add that these patients should still receive the standard six-week treatment.

The study involved 228 patients treated at Mayo Clinic in Minnesota and Arizona. The researchers say that this study represents the largest cohort of postsurgical de-escalation patients in the published literature.

Further, ongoing research will continue to explore using biomarkers such as circulating DNA to find the best patient populations for this treatment strategy.

Review the paper for a complete list of authors, disclosures and funding. 

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

About Mayo Clinic Comprehensive Cancer Center 
Designated as a comprehensive cancer center by the National Cancer Institute, Mayo Clinic Comprehensive Cancer Center is defining the cancer center of the future, focused on delivering the world's most exceptional patient-centered cancer care for everyone. At Mayo Clinic Comprehensive Cancer Center, a culture of innovation and collaboration is driving research breakthroughs in cancer detection, prevention and treatment to change lives.

Media contact:

• Kelley Luckstein, Mayo Clinic Communications, newsbureau@mayo.edu

The post Shorter, less intense radiation-chemo regimen effective for HPV-linked oropharyngeal cancer, Mayo study shows appeared first on Mayo Clinic News Network.

Kenneth Adams understands the importance of love, resilience and family. After his wife's passing in 2022, Adams reconnected with a lifelong friend, whom he had known for nearly 50 years. Kenneth and Susan Kidd eventually fell in love, and they were committed to building a life together.

"We love to travel and spend time with family — we wanted our relationship to be an example for our grandchildren. And to us, marriage was the next step," Adams said.

While making plans for a wedding in early 2025, Kenneth became ill and was diagnosed with sepsis. His complex condition required coordinated care, so the team at Mayo Clinic developed a plan: antibiotics administered intravenously every day for six weeks. Instead of staying in the hospital for the duration of the treatment, Kenneth's care team determined he was a candidate for Mayo Clinic's Advanced Care at Home program.

Going home

Advanced Care at Home offers patients high-acuity care, delivered in the comfort of their home. With around-the-clock access, advanced technology and a dedicated in-home care team, patients receive comprehensive treatment while minimizing stress and disruption to daily life. 

"With Advanced Care at Home, we can treat, monitor and communicate with patients as we would in a hospital setting, without recreating the feeling of being in a hospital setting," says Dr. Michael Maniaci, director of Advanced Care at Home.

For Kenneth, receiving treatment at home allowed him to maintain his routine, enjoy meals and sleep without interruption. 

“The program provided everything you would need in a hospital but with the comforts of home and closeness of family," Kenneth says. "They had the procedures down, the infrastructure and the systems in place — it was a dream come true."

As the end of his treatment neared and his strength improved, Kenneth and Susan began thinking about a wedding ceremony again.

A wedding between treatments

On May 19, 2025, Kenneth and Susan invited a pair of close friends and a pastor to their Ponte Vedra, Florida, home. The couple was married in their backyard, and just an hour after saying "I do," Kenneth received one of his daily treatments.

"Getting married was a goal for Mr. Adams, so as his care team, we made sure he could achieve that goal safely and on his terms," Dr. Maniaci says.

Kenneth credits Advanced Care at Home with making the wedding possible. He was discharged from the program a week later with no signs of sepsis. 

“People heal better at home," he says. “I feel that I'm living proof of that. There was no burden on my family — the team handled everything – and by being at home, I could get married,” Kenneth says.

By late July, Kenneth was well enough to resume another passion: travel. A trip that had been postponed earlier in the year was back on the calendar as a honeymoon. Looking ahead, Kenneth is preparing for an annual family trip in October. He continues to live with purpose and gratitude. 

“I want to do what I can, while I can,” Kenneth says. "I can do so much more with my health restored."

The post How Advanced Care at Home helped make Kenneth Adams’ wedding day possible appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — The immune system is meant to protect the body from infection and disease. But with age, it can become less capable of doing so. However, Mayo Clinic researchers have found that some older people maintain "immune youth" – a new term coined by Mayo researchers to explain a young immune system in someone over age 60.

"We are studying why some individuals have a 'fountain of youth' in their immune systems. We want to learn from them," says Cornelia Weyand, M.D., Ph.D., a Mayo Clinic rheumatologist and clinician-scientist. She is a lead author on a perspective paper published in Nature Aging.

Dr. Weyand's research team discovered this cellular fountain of youth in more than 100 older patients who came to Mayo Clinic to receive treatment for an autoimmune disease that affects the arteries, including the aorta, called giant cell arteritis. Dr. Weyand and colleagues found in the diseased tissue of these patients specialized immune cells, called stem-like T cells. These immune cells behave like young stem cells that usually regenerate and aid healing and growth; but in this case, they were spreading the disease. This team of researchers also discovered autoimmune stem cells in humans previously.

"We observed that these patients have very young immune systems despite being in their 60s and 70s. But the price they pay for that is autoimmunity," she says.

Autoimmunity is when the immune system mistakenly attacks healthy tissues and organs.

In addition, the researchers saw that the immune checkpoint inhibitors that regulate the immune system were not working properly.

Benefits of immune system aging

"Contrary to what one may think, there are benefits to having an immune system that ages in tandem with the body," says Jörg Goronzy, M.D., Ph.D., a Mayo Clinic researcher on aging who is a co-lead author of the paper. "We need to consider the price to pay for immune youthfulness. That price can be autoimmune disease."

Immune aging is a sophisticated adaptation mechanism that the immune system can use to prevent autoimmune disease, say the researchers.

They are in the process of developing new diagnostic tests that will help find patients and healthy individuals who carry high numbers of immune stem cells and may be predisposed to autoimmune disease later in life. The research is part of a larger effort at Mayo Clinic called the Precure initiative, focused on developing tools that empower clinicians to predict and intercept biological processes before they evolve into disease or progress into complex, hard-to-treat conditions.

Review the study for a complete list of authors, disclosures and funding. 

Additional resources:
Mayo Clinic advances research on mysterious blood vessel disease

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Alison Satake, Mayo Clinic Communications, newsbureau@mayo.edu

The post Mayo Clinic researchers discover the immune system’s ‘fountain of youth’ appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — Scientific breakthroughs in one disease don't always shed light on treating other diseases. But that's been the surprising journey of one Mayo Clinic research team. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1 diabetes, once known as juvenile diabetes.

Type 1 diabetes is a chronic autoimmune condition in which the immune system errantly attacks pancreatic beta cells that produce insulin. The disease is caused by genetic and other factors and affects an estimated 1.3 million people in the U.S.

In their studies, the Mayo Clinic researchers took a cancer mechanism and turned it on its head. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells.

"Our findings show that it's possible to engineer beta cells that do not prompt an immune response," says immunology researcher Virginia Shapiro, Ph.D., principal investigator of the study, published in the Journal of Clinical Investigation.

A few years ago, Dr. Shapiro's team demonstrated that an enzyme, known as ST8Sia6, that increases sialic acid on the surface of tumor cells helps tumor cells appear as though they are not foreign entities to be targeted by the immune system.  

"The expression of this enzyme basically ‘sugar coats' cancer cells and can help protect an abnormal cell from a normal immune response. We wondered if the same enzyme might also protect a normal cell from an abnormal immune response," Dr. Shapiro says. The team first established proof of concept in an artificially-induced model of diabetes.

In the current study, the team looked at preclinical models that are known for the spontaneous development of autoimmune (type 1) diabetes, most closely approximating the process that occurs in patients. Researchers engineered beta cells in the models to produce the ST8Sia6 enzyme.

In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.

Importantly, the researchers also found the immune response to the engineered cells appears to be highly specific, says M.D.-Ph.D. student Justin Choe, first author of the publication. Choe conducted the study in the Ph.D. component of his dual degree at Mayo Clinic Graduate School of Biomedical Sciences and Mayo Clinic Alix School of Medicine.

"Though the beta cells were spared, the immune system remained intact," Choe says. The researchers were able to see active B- and T-cells and evidence of an autoimmune response against another disease process. "We found that the enzyme specifically generated tolerance against autoimmune rejection of the beta cell, providing local and quite specific protection against type 1 diabetes."

No cure currently exists for type 1 diabetes, and treatment involves using synthetic insulin to regulate blood sugar, or, for some people, undergoing a transplant of pancreatic islet cells, which include the much-needed beta cells. Because transplantation involves immunosuppression of the entire immune system, Dr. Shapiro aims to explore using the engineered beta cells in transplantable islet cells with the goal of ultimately improving therapy for patients.

"A goal would be to provide transplantable cells without the need for immunosuppression," says Dr. Shapiro. "Though we're still in the early stages, this study may be one step toward improving care."

The research was funded by grants from the National Institutes of Health.

Please see the study for the full list of authors.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Kelley Luckstein, Mayo Clinic Communications, newsbureau@mayo.edu

The post Mayo Clinic researchers find ‘sugar coating’ cells can protect those typically destroyed in type 1 diabetes appeared first on Mayo Clinic News Network.

Researchers are leading the nation in using powerful and precise radioactive drugs to treat people with complex cancers.  

ROCHESTER, Minn. — Mayo Clinic has treated the first person in the U.S. using a novel radioactive medicine for advanced breast cancer as part of an international multisite clinical trial.

The medicine used in this clinical trial contains actinium-225, a highly potent alpha-emitting radiopharmaceutical therapy that was first developed for a subtype of gastroenteropancreatic neuroendocrine tumors, which are rare and can form in the pancreas and the gastrointestinal tract. The alpha-emitting radiopharmaceutical therapy is intended to work by passing through the blood to stick to cancer cells, delivering powerful and precise radiation without harming healthy cells.

The Mayo Clinic researchers are the first to apply this therapy in America to a patient with metastatic breast cancer. The phase 1b/2 open-label trial is being conducted at all three academic Mayo Clinic sites in Rochester, Minnesota; Phoenix; Jacksonville, Florida; and approximately 20 other sites across the U.S. The first person treated was at Mayo Clinic in Florida.

The principal investigator at Mayo Clinic is Geoffrey Johnson, M.D., Ph.D., a professor of radiology and a leader in radiopharmaceutical therapies. He says these are innovative cancer treatments that use radioactive medicines designed to target and kill cancer cells with high precision.

Mayo Clinic has nearly 20 active radiopharmaceutical therapy clinical trials, with 10 more preparing to launch, targeting many different types of cancer. Mayo Clinic in Rochester treats more patients with modern radiopharmaceutical therapies, such as lutetium dotatate for neuroendocrine cancers and lutetium PSMA for prostate cancers, than any other center in the world.

Lutetium dotatate and lutetium PSMA are beta-emitting radiopharmaceuticals. They use beta particles, which are tiny subatomic particles, to radiate at a low level. In contrast, alpha-emitting radiopharmaceuticals use alpha particles that are 8,000 times more massive than beta particles, and travel only three cell diameters after they are emitted from the therapy.

"This means alpha emitters can deliver a much more powerful impact over a shorter distance. If you consider killing a cancer cell is like knocking down a brick wall, then the difference is like throwing a 10-pound dumbbell (beta) at the wall versus a fully loaded Mack truck (alpha)," says Dr. Johnson. "The alpha emitter's potential lies in its power and in its ability to precisely kill even a single cancer cell without injuring surrounding healthy tissue, making it a next-generation therapy."

In preclinical studies, data indicates actinium-225 DOTATATE that targets the somatostatin receptor subtype 2expression demonstrated feasibility and potential efficacy for treatment of ER+ metastatic breast cancer in the laboratory. The drug was developed by RayzeBio Inc., a Bristol Myers Squibb Company, the sponsor of the active phase 1b/2 clinical trial.

Study Title: Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects with Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates And/or Chemotherapy (TRACY-1)

• Descriptor: Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and with pembrolizumab in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
• Sponsor: RayzeBio Inc.
• Link: https://clinicaltrials.gov/study/NCT06590857

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and to providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Brittany Cordeiro, Mayo Clinic Communications, newsbureau@mayo.edu

The post Mayo Clinic treats first person in the US with a novel radiopharmaceutical therapy for breast cancer appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — Mayo Clinic again leads U.S. News & World Report’s "Best Hospitals" rankings for 2025-2026 – the 36^th time since the rankings began. This sustained distinction includes a place on the Honor Roll and more specialties ranked in the top three than any other hospital in the nation.

"We are proud to once again be recognized as a leader in healthcare, a reflection of the unwavering commitment of our staff and their dedication to excellence, innovation and putting patients first," says Gianrico Farrugia, M.D., Mayo Clinic president and CEO. "This honor reinforces our continued focus on raising the standard of what’s possible in medicine."

This recognition comes as Mayo Clinic continues to make major investments in shaping the future of healthcare through Mayo Clinic Platform and Bold. Forward. Unbound., which seamlessly blends physical spaces with digital technologies to create new healthcare experiences for patients and staff. This includes integrating artificial intelligence, robotics and automation with a human touch to address patients’ unmet and evolving needs.

U.S. News & World Report’s Honor Roll features the top 20 U.S. hospitals that earn the most points across 15 specialties and 22 procedures and conditions. Mayo Clinic is the only healthcare organization with two hospitals on the list—Mayo Clinic in Arizona marks its ninth consecutive year and Mayo Clinic in Rochester again earned the highest overall point total.

State and regional rankings

Mayo Clinic again ranks No. 1 in the U.S. News state rankings for Minnesota and Arizona and continues to be the top hospital in the Jacksonville metro area. Mayo Clinic Health System in Eau Claire, Wisconsin, has also been recognized as a "Best Regional Hospital" in Northwestern Wisconsin.

"Being top-ranked year after year isn’t just about accolades – it’s about consistent, reliable excellence," said Sean Dowdy, M.D., chief value officer at Mayo Clinic. "Real quality means providing world-class care, even under pressure and through change. Our teams stay focused on what matters most: the patient."

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and to providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Tia Ford, Mayo Clinic Communications, newsbureau@mayo.edu

The post Mayo Clinic top-ranked in most specialties for 36 straight years in U.S. News & World Report rankings appeared first on Mayo Clinic News Network.